SuperworthLisata Therapeutics LSTA
- Market cap
- $9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −137.3%
Lisata Therapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | $0 | $0 | $1M | n/a | $70K | $0 | $100K−90% | n/a | $0 | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $3.4M+1% | $3M−6% | $3.2M+2% | $2.6M−18% | $2.5M−25% | $3M−2% | $2.6M−20% | $2.3M−13% | $2M−23% | $1.1M−62% | $1.2M−54% | $584K−74% |
| SG&A | $2.6M−35% | $3M−9% | $3.4M−8% | $2.9M−21% | $2.8M+8% | $3M−0% | $3.2M−3% | $2.7M−8% | $2.5M−12% | $2M−32% | $3.7M+15% | $3.4M+27% |
| −$6M−84% | −$6M−8% | −$6.6M−4% | −$5.5M−20% | −$5.3M−11% | −$4.9M−18% | −$5.8M−11% | −$4.9M−12% | −$4.4M−17% | −$3.1M−38% | −$4.9M−16% | −$4M−18% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$5.3M−86% | −$5.4M−10% | −$6.2M+0% | −$5M−21% | −$4.9M−6% | −$4.6M−14% | −$5.7M−8% | −$4.7M−8% | −$4.2M−14% | −$3M−36% | −$4.9M−14% | −$2.9M−37% |
| $0 | $0 | −$798K | $0 | $0 | $0 | −$962K+21% | $0 | $0 | $0 | −$387K−60% | $0 | |
| Net income | −$5.3M−86% | −$5.4M−10% | −$5.4M−13% | −$5M+25% | −$4.9M−6% | −$4.6M−14% | −$4.7M−13% | −$4.7M−8% | −$4.2M−14% | −$3M−36% | −$4.5M−5% | −$2.9M−37% |
| −$0.65−92% | −$0.66−13% | −$0.65−16% | −$0.61+22% | −$0.59−9% | −$0.55−17% | −$0.55−15% | −$0.54−12% | −$0.49−17% | −$0.34−38% | −$0.50−9% | −$0.32−41% | |
| 8.1M+72% | 8.1M+4% | 8.3M+4% | 8.3M+4% | 8.3M+2% | 8.4M+3% | 8.6M+4% | 8.6M+4% | 8.7M+5% | 8.8M+5% | 9M+5% | 9.1M+6% |
Gross profit: 13 periods, Q1 FY14 to Q1 FY17: not printed by the filing, worked out from its own lines.
EPS, diluted: Q4 FY13 and Q4 FY14: quarter's net income to common over its shares, to the cent, the shares from counts implied by EPS, near the year's EPS less the nine months'. 10 periods, Q4 FY16 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 10 periods, Q4 FY16 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Lisata Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LSTALisata Therapeutics | $9M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Lisata Therapeutics
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .